Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma
Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment
HAYWARD, CaliforniaKosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment. Approximately 470 patients with first-relapse disease will be randomized to treatment with bortezomib (Velcade) plus tanespimycin or bortezomib alone.
Articles in this issue
NLST article not balanced, critic of screening trial asserts
M.D. Anderson and AstraZeneca form neuropathic pain alliance
Good nilotinib responses in imatinib-resistant AP-CML
Virus linked to Merkel cell carcinoma
Benefit of adjuvant RT/CT for pancreatic ca affirmed
Recurrence Score helps select node+ pts for chemo
For resectable liver mets: Preop chemotherapy or not?
Plerixafor boosts stem cell mobilization in myeloma pts
MRI shows second-hand smoke damage
Assay has high sensitivity for hard-to-detect SLN mets
Dasatinib effective in imatinib resistant/intolerant CML
ONI remembers Judah Folkman, founder of angiogenesis
New machine approved for adaptive RT
ONI sits down with Dr. Vincent DeVita
Making faster, better, more cost-effective clinical trials
Recent Videos
Related Content
